Frontiers in Oncology (Apr 2023)
Evaluation of second-line apatinib plus irinotecan as a treatment for advanced gastric adenocarcinoma or gastroesophageal conjunction adenocarcinoma: a prospective, multicenter phase II trial
- Jinglei Qu,
- Jinglei Qu,
- Jinglei Qu,
- Jinglei Qu,
- Xin He,
- Xin He,
- Xin He,
- Xin He,
- Ying Luo,
- Ying Luo,
- Ying Luo,
- Ying Luo,
- Ping Yu,
- Ping Yu,
- Ping Yu,
- Ping Yu,
- Ying Chen,
- Ying Chen,
- Ying Chen,
- Ying Chen,
- Jing Liu,
- Xin Wang,
- Chang Wang,
- Tingting Liang,
- Yuxian Bai,
- Yu Han,
- Li Man,
- Chuanchun Leng,
- Caiyun Zhou,
- Lijie He,
- Xin Wang,
- Yunpeng Liu,
- Yunpeng Liu,
- Yunpeng Liu,
- Yunpeng Liu,
- Xiujuan Qu,
- Xiujuan Qu,
- Xiujuan Qu,
- Xiujuan Qu
Affiliations
- Jinglei Qu
- Department of Medical Oncology, The First Hospital of China Medical University, China Medical University, Shenyang, China
- Jinglei Qu
- Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China
- Jinglei Qu
- Liaoning Province Clinical Research Center for Cancer, Shenyang, China
- Jinglei Qu
- Clinical Cancer Research Center of Shenyang, The First Hospital of China Medical University, Shenyang, China
- Xin He
- Department of Medical Oncology, The First Hospital of China Medical University, China Medical University, Shenyang, China
- Xin He
- Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China
- Xin He
- Liaoning Province Clinical Research Center for Cancer, Shenyang, China
- Xin He
- Clinical Cancer Research Center of Shenyang, The First Hospital of China Medical University, Shenyang, China
- Ying Luo
- Department of Medical Oncology, The First Hospital of China Medical University, China Medical University, Shenyang, China
- Ying Luo
- Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China
- Ying Luo
- Liaoning Province Clinical Research Center for Cancer, Shenyang, China
- Ying Luo
- Clinical Cancer Research Center of Shenyang, The First Hospital of China Medical University, Shenyang, China
- Ping Yu
- Department of Medical Oncology, The First Hospital of China Medical University, China Medical University, Shenyang, China
- Ping Yu
- Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China
- Ping Yu
- Liaoning Province Clinical Research Center for Cancer, Shenyang, China
- Ping Yu
- Clinical Cancer Research Center of Shenyang, The First Hospital of China Medical University, Shenyang, China
- Ying Chen
- Department of Medical Oncology, The First Hospital of China Medical University, China Medical University, Shenyang, China
- Ying Chen
- Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China
- Ying Chen
- Liaoning Province Clinical Research Center for Cancer, Shenyang, China
- Ying Chen
- Clinical Cancer Research Center of Shenyang, The First Hospital of China Medical University, Shenyang, China
- Jing Liu
- Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China
- Xin Wang
- Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, Shenyang, China
- Chang Wang
- Cancer Center, The First Hospital of Jilin University, Changchun, China
- Tingting Liang
- Cancer Center, The First Hospital of Jilin University, Changchun, China
- Yuxian Bai
- Department of Gastrointestinal Oncology, Harbin Medical University Cancer Hospital, Harbin, China
- Yu Han
- Department of Gastrointestinal Oncology, Harbin Medical University Cancer Hospital, Harbin, China
- Li Man
- Department of Medical Oncology, Anshan Cancer Hospital, Anshan, China
- Chuanchun Leng
- 0Department of Medical Oncology, The Central Hospital of Anshan, Anshan, China
- Caiyun Zhou
- 1The Fourth Oncology Departments, Huludao Central Hospital, Huludao, China
- Lijie He
- 2Department of Medical Oncology, People’s Hospital of Liaoning Province, Shenyang, China
- Xin Wang
- 3Department of Medical Oncology, General Hospital of Benxi Iron and Steel Industry Group of Liaoning Health Industry Group, Benxi, China
- Yunpeng Liu
- Department of Medical Oncology, The First Hospital of China Medical University, China Medical University, Shenyang, China
- Yunpeng Liu
- Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China
- Yunpeng Liu
- Liaoning Province Clinical Research Center for Cancer, Shenyang, China
- Yunpeng Liu
- Clinical Cancer Research Center of Shenyang, The First Hospital of China Medical University, Shenyang, China
- Xiujuan Qu
- Department of Medical Oncology, The First Hospital of China Medical University, China Medical University, Shenyang, China
- Xiujuan Qu
- Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China
- Xiujuan Qu
- Liaoning Province Clinical Research Center for Cancer, Shenyang, China
- Xiujuan Qu
- Clinical Cancer Research Center of Shenyang, The First Hospital of China Medical University, Shenyang, China
- DOI
- https://doi.org/10.3389/fonc.2023.1072943
- Journal volume & issue
-
Vol. 13
Abstract
ObjectiveApatinib and irinotecan are used as systematic therapies for advanced gastric adenocarcinoma (GAC) and gastroesophageal junction adenocarcinoma (GEJA), while the evidence for their combination as second-line therapy in these patients is limited. This study aimed to evaluate the efficacy and safety of second-line apatinib plus irinotecan for the treatment of GAC and GEJA.MethodsIn this prospective, multicenter phase II clinical study, 28 patients with advanced GAC or GEJA who received second-line apatinib plus irinotecan were recruited.ResultsIn total, 1 (3.6%) patient achieved complete response, 7 (25.0%) patients achieved partial response, 13 (46.4%) patients had stable disease, and 4 (14.3%) patients showed progressive disease, while clinical response was not evaluable or not assessed in 3 (10.7%) patients. The objective response rate and disease control rate were 28.6% and 75.0%, respectively. Meanwhile, the median (95% confidence interval (CI)) progression-free survival (PFS) was 4.5 (3.9-5.1) months, and the median (95% CI) overall survival (OS) was 11.3 (7.4-15.1) months. By multivariate Cox regression analysis, male sex, liver metastasis, and peritoneal metastasis were independently associated with worse PFS or OS, while treatment duration ≥5 months was independently associated with better OS. In terms of the safety profile, 89.3% of patients experienced treatment-emergent adverse events of any grade, among which 82.1% of patients had grade 1-2 adverse events and 64.3% of patients had grade 3-4 adverse events.ConclusionApatinib plus irinotecan as second-line therapy achieves a good treatment response and satisfactory survival with tolerable safety in patients with advanced GAC or GEJA.
Keywords
- second-line apatinib plus irinotecan
- gastric adenocarcinoma
- gastroesophageal junction adenocarcinoma
- treatment efficacy
- safety
